Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Leukemia symbols : Nvs save search
Global Acute Lymphoblastic Leukemia Therapeutics Market Research 2024-2033: Developments Review, Regulatory Landscape, Competitive Benchmarking, Dynamic Landscape
Published: 2024-03-29 (Crawled : 18:00) - prnewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
| Email alert
Add to watchlist
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
| Email alert
Add to watchlist
GMAB | News | $28.54 -1.48% -1.51% 560K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $95.11 6.88% 490
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | News | $289.67 3.83% 5.3K
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
| Email alert
Add to watchlist
research global leukemia therapeutics market
Global Hairy Cell Leukemia Market Analysis & Forecast 2024-2034
Published: 2024-02-02 (Crawled : 03:00) - prnewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.5%
H: 0.26%
C: -1.03%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 1.23%
H: 1.5%
C: -1.14%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 3.59%
H: 0.0%
C: 0.0%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.28%
H: 0.66%
C: -0.14%
cell global leukemia market
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
Published: 2024-01-08 (Crawled : 07:00) - globenewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.89%
H: 0.12%
C: -0.17%
scemblix leukemia trial response molecular
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
Published: 2022-06-24 (Crawled : 12:00) - globenewswire.com
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: 6.71%
H: 0.0%
C: -0.1%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
scemblix treatment chmp novartis leukemia positive
Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Published: 2022-06-07 (Crawled : 15:00) - globenewswire.com
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: -2.41%
H: 0.65%
C: 0.42%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
scemblix novartis leukemia trial
Acute Myeloid Leukemia (AML) Treatment Market size in APAC to grow by USD 277.03 Million | Driven by high incidence of acute myeloid leukemia | Technavio
Published: 2022-03-07 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
ALPMY | News | $9.53 -1.11% 690K
|
Manufacturing
|
| O: 1.58%
H: 0.0%
C: -0.87%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
treatment myeloid leukemia leukemia acute myeloid leukemia aml
Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia
Published: 2021-12-11 (Crawled : 00:20) - globenewswire.com
NVSEF | News | $95.11 6.88% 490
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
| Email alert
Add to watchlist
scemblix novartis myeloid leukemia leukemia response
Global Acute Myeloid Leukemia (AML) Therapeutics Market Report 2021-2026: Ballooning Elderly Population - The Vital Growth Driver for AML Therapeutics
Published: 2021-12-06 (Crawled : 12:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200
|
Health Technology
|
| O: -1.49%
H: 1.45%
C: 0.92%
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: 2.02%
H: 0.04%
C: -0.89%
IMNPQ | $0.001
|
Manufacturing
|
| O: 50.0%
H: 0.0%
C: -33.33%
ALPMY | News | $9.53 -1.11% 690K
|
Manufacturing
|
| O: -3.39%
H: 3.45%
C: 3.3%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
MEIP | $3.31 -1.78% -1.81% 5K
|
Health Technology
|
| O: -4.4%
H: 0.0%
C: 0.0%
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
|
| O: -2.16%
H: 0.0%
C: 0.0%
CYCC | $1.805 3.14% 3.05% 28K
|
Health Technology
|
| O: -5.93%
H: 0.0%
C: 0.0%
CTIC | $9.09 0.05% 11M
|
Health Technology
|
| O: 7.24%
H: 0.0%
C: 0.0%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 2.53%
H: 0.0%
C: 0.0%
AGIO | $31.82 5.33% 5.06% 1.2M
|
Health Technology
|
| O: -5.47%
H: 0.0%
C: 0.0%
myeloid leukemia leukemia therapeutics growth acute myeloid leukemia aml
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
Published: 2021-11-01 (Crawled : 15:00) - biospace.com/
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 1.3%
H: 0.0%
C: 0.0%
treatment fda myeloid leukemia leukemia fda approval
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
Published: 2021-10-29 (Crawled : 20:00) - globenewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $95.11 6.88% 490
|
Health Technology
| Email alert
Add to watchlist
treatment fda myeloid leukemia leukemia fda approval
Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach $976.2 Billion by 2026
Published: 2021-08-11 (Crawled : 12:00) - prnewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.51%
H: 0.13%
C: -0.27%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.3%
H: 0.16%
C: -1.25%
MEIP | $3.31 -1.78% -1.81% 5K
|
Health Technology
|
| O: 0.37%
H: 0.36%
C: 0.0%
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
|
| O: -0.09%
H: 1.32%
C: 0.35%
CYCC | $1.805 3.14% 3.05% 28K
|
Health Technology
|
| O: -0.19%
H: 0.19%
C: -0.76%
CTIC | $9.09 0.05% 11M
|
Health Technology
|
| O: 1.73%
H: 0.34%
C: -7.14%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.52%
H: 0.38%
C: -0.44%
AGIO | $31.82 5.33% 5.06% 1.2M
|
Health Technology
|
| O: 0.07%
H: 1.52%
C: -0.32%
myeloid leukemia leukemia acute myeloid leukemia aml
Global Leukemia Therapeutics Markets, 2016-2020 & 2021-2026 - Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, & Others
Published: 2021-04-21 (Crawled : 17:00) - prnewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.56%
H: 0.72%
C: 0.38%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.5%
H: 0.76%
C: -0.32%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.67%
H: 0.56%
C: -0.3%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.7%
H: 1.5%
C: 0.92%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 1.24%
H: 0.48%
C: 0.36%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.49%
H: 0.23%
C: -0.63%
immunotherapy stem cell therapy leukemia
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.